These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32121135)

  • 1. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy).
    Scaglione V; Mazzitelli M; Costa C; Pisani V; Greco G; Serapide F; Lionello R; La Gamba V; Marascio N; Trecarichi EM; Torti C
    Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32121135
    [No Abstract]   [Full Text] [Related]  

  • 2. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
    Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
    Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
    Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
    World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2 and 3 in northwest China.
    Yang Y; Wu FP; Wang WJ; Shi JJ; Li YP; Zhang X; Dang SS
    World J Gastroenterol; 2019 Nov; 25(44):6551-6560. PubMed ID: 31802834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
    Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
    BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response.
    Bruno S; Di Marco V; Iavarone M; Roffi L; Boccaccio V; Crosignani A; Cabibbo G; Rossi S; Calvaruso V; Aghemo A; Giacomelli L; Craxì A; Colombo M; Maisonneuve P
    Liver Int; 2017 Oct; 37(10):1526-1534. PubMed ID: 28418617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low incidence of HCC in chronic hepatitis C patients with pretreatment liver stiffness measurements below 17.5 kilopascal who achieve SVR following DAAs.
    Søholm J; Hansen JF; Mössner B; Røge BT; Lauersen A; Hansen JB; Weis N; Barfod TS; Lunding S; Øvrehus A; Mohey R; Thielsen P; Christensen PB
    PLoS One; 2020; 15(12):e0243725. PubMed ID: 33301499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virological response to direct-acting antiviral regimens reduces the risk of hepatocellular carcinoma in HIV/HCV-coinfected patients with cirrhosis.
    Merchante N; Rivero-Juárez A; Téllez F; Merino D; Ríos-Villegas MJ; Villalobos M; Omar M; Rincón P; Rivero A; Pérez-Pérez M; Raffo M; López-Montesinos I; Palacios R; Gómez-Vidal MA; Macías J; Pineda JA;
    J Antimicrob Chemother; 2018 Sep; 73(9):2435-2443. PubMed ID: 29982683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
    Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment.
    McKnight AH; Townsend ML; Hashem MG; Naggie S; Park LP; Britt RB
    Ann Pharmacother; 2020 Nov; 54(11):1057-1064. PubMed ID: 32406244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
    Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
    AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model.
    Petta S; Di Marco V; Bruno S; Enea M; Calvaruso V; Boccaccio V; Rossi S; Craxì A; Cammà C
    Liver Int; 2016 Dec; 36(12):1765-1773. PubMed ID: 27164508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to direct-acting antiviral therapy among ongoing drug users and people receiving opioid substitution therapy.
    Macías J; Morano LE; Téllez F; Granados R; Rivero-Juárez A; Palacios R; Ríos M; Merino D; Pérez-Pérez M; Collado A; Figueruela B; Morano A; Freyre-Carrillo C; Martín JM; Rivero A; García F; Pineda JA;
    J Hepatol; 2019 Jul; 71(1):45-51. PubMed ID: 30853642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension.
    Di Marco V; Calvaruso V; Ferraro D; Bavetta MG; Cabibbo G; Conte E; Cammà C; Grimaudo S; Pipitone RM; Simone F; Peralta S; Arini A; Craxì A
    Gastroenterology; 2016 Jul; 151(1):130-139.e2. PubMed ID: 27039970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of direct-acting antiviral therapy for hepatitis C in difficult-to-treat patients in a safety-net health system: a retrospective cohort study.
    Yek C; de la Flor C; Marshall J; Zoellner C; Thompson G; Quirk L; Mayorga C; Turner BJ; Singal AG; Jain MK
    BMC Med; 2017 Nov; 15(1):204. PubMed ID: 29151365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.